The role of UFT in advanced gastric cancer

Aykan N. F. , Idelevich E.

ANNALS OF ONCOLOGY, cilt.19, ss.1045-1052, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 19 Konu: 6
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1093/annonc/mdn024
  • Sayfa Sayıları: ss.1045-1052


Background: Advanced gastric cancer has a poor prognosis, with a relative 5-year survival rate of 7%-27%. Chemotherapy, which improves overall survival (OS) and quality of life, is the main treatment option. Although numerous regimens have been investigated, there is no standard treatment. Combination chemotherapy, however, is associated with a significant survival benefit compared with monotherapy and i.v. 5-fluorouracil (5-FU) is one of the most widely used agents. UFT (tegafur-uracil) has similar efficacy to continuous infusion 5-FU with improved tolerability and is more convenient for patients.